Quality of life considerations in gynecologic cancer

被引:102
作者
Penson, Richard T.
Wenzel, Lari B.
Vergote, Ignace
Cella, David
机构
[1] Univ Calif Irvine, Ctr Hlth Policy Res, Coll Med, Irvine, CA 92697 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Katholieke Univ Leuven Hosp, Dept Gynaecol Oncol, Louvain, Belgium
[4] Northwestern Univ, Evanston, IL USA
[5] Evanston NW Healthcare, Evanston, IL USA
关键词
D O I
10.1016/S0020-7292(06)60040-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Quality of life (QOL) is a fundamental consideration for patients with life threatening diseases. Major evolving paradigms are discussed: improved QOL with laparoscopic surgery, the impact on QOL of intraperitoneal chemotherapy for optimally cytoreduced ovarian cancer, combination therapy, sexuality, and survivorship. The goals of treatment for many patients with gynecologic tumors remain largely palliative, and patient reported QOL is the primary outcome determining the utility of treatment. Particularly in this area, QOL endpoints are increasingly important in clinical trials. The QOL issues facing gynecologic cancer patients, the use of validated QOL instruments, recent advances in the evaluation of interventions, and changes in concepts related to QOL are reviewed. (c) 2006 International Federation of Gynecology and Obstetrics. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S247 / S257
页数:11
相关论文
共 91 条
[61]   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J].
Ozols, RF ;
Bundy, BN ;
Greer, BE ;
Fowler, JM ;
Clarke-Pearson, D ;
Burger, RA ;
Mannel, RS ;
DeGeest, K ;
Hartenbach, EM ;
Baergen, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3194-3200
[62]  
Parmar MKB, 2003, LANCET, V361, P2099
[63]   Interval debulking surgery in advanced epithelial ovarian cancer [J].
Pecorelli, S ;
Odicino, F ;
Favalli, G .
BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY, 2002, 16 (04) :573-583
[64]  
Phillips NA, 2000, AM FAM PHYSICIAN, V62, P127
[65]   Quality of life: Gynaecological cancers [J].
Pignata, S ;
Ballatori, E ;
Favalli, G ;
Scambia, G .
ANNALS OF ONCOLOGY, 2001, 12 :S37-S42
[66]   Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel:: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study -: art. no. 5 [J].
Pignata, S ;
De Placido, S ;
Biamonte, R ;
Scambia, G ;
Di Vagno, G ;
Colucci, G ;
Febbraro, A ;
Marinaccio, M ;
Lombardi, AV ;
Manzione, L ;
Cartenì, G ;
Nardi, M ;
Danese, S ;
Valerio, MR ;
de Matteis, A ;
Massidda, B ;
Gasparini, G ;
Di Maio, M ;
Pisano, C ;
Perrone, F .
BMC CANCER, 2006, 6 (1)
[67]   Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study [J].
Randall, ME ;
Filiaci, VL ;
Muss, H ;
Spirtos, NM ;
Mannel, RS ;
Fowler, L ;
Thigpen, JT ;
Benda, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :36-44
[68]   Type II radical hysterectomy: Evaluating its role in cervical cancer [J].
Rose, PG .
GYNECOLOGIC ONCOLOGY, 2001, 80 (01) :1-2
[69]   Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer [J].
Rose, PG ;
Bundy, BN ;
Watkins, EB ;
Thigpen, JT ;
Deppe, G ;
Maiman, MA ;
Clarke-Pearson, DL ;
Insalaco, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (15) :1144-1153
[70]   Secondary surgical cytoreduction for advanced ovarian carcinoma [J].
Rose, PG ;
Nerenstone, S ;
Brady, MF ;
Clarke-Pearson, D ;
Olt, G ;
Rubin, SC ;
Moore, DH ;
Small, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2489-2497